SCHEMBL11930754

SCHEMBL11930754

Cc1cc(C[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc1O

nearest known ligand 0.74

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 15/20 0.74
NAALAD2 Q9Y3Q0 6/20 0.68
RIMKLA Q8IXN7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21345485 0.90 FOLH1 (0.60) FOLH1NAALAD2RIMKLA
SCHEMBL4139164 0.85 FOLH1 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL1740438 0.85 FOLH1 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL11977627 0.83 NAALAD2 (0.77) FOLH1NAALAD2RIMKLA
SCHEMBL9965331 0.81 NAALAD2 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL13515316 0.81 NAALAD2 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL4316981 0.81 NAALAD2 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL14729495 0.79 FOLH1 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL22712934 0.79 FOLH1 (1.00) FOLH1NAALAD2RIMKLA
SCHEMBL18145693 0.79 FOLH1 (1.00) FOLH1NAALAD2RIMKLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID CITIZENS BANK, N.A. 2021-08-12 US disclosed
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 US disclosed
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2021-03-11 US disclosed
US-10640461-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2020-05-05 US disclosed
US-20180111895-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2018-04-26 US disclosed
US-9878980-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2018-01-30 US disclosed
US-9878980-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2018-01-30 US disclosed
US-20170044098-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2017-02-16 US disclosed
US-20170044098-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2017-02-16 US disclosed
US-20160279235-A1 Heterodimers of Glutamic Acid CITIZENS BANK, N.A. 2016-09-29 US disclosed
US-9309193-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2016-04-12 US disclosed
US-8487129-B2 Heterodimers of glutamic acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2013-07-16 US disclosed
US-20120328518-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS PIRAMAL IMAGING SA (CH) 2012-12-27 US disclosed
US-20120269726-A1 Heterodimers of Glutamic Acid MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2012-10-25 US disclosed
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8211401-B2 Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2012-07-03 US disclosed
WO-2011073286-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-06-23 WO disclosed
US-20100178246-A1 TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2010-07-15 US disclosed
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID MOLECULAR INSIGHT PHARMACEUTICALS, INC. 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100178246-A1 TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA PSMA1, PSMA5, PSMA3 FOLH1 4/4885NAALAD2 339/4885RIMKLA 601/4885
US-20210070695-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885
US-20160279235-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885
US-20120269726-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885
US-20080193381-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885
US-20210070696-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885
US-20120208988-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885
US-10640461-B2 Heterodimers of glutamic acid DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885
US-20210246103-A1 HETERODIMERS OF GLUTAMIC ACID DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885
US-20170044098-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 9/4885RIMKLA 6/4885
US-20120328518-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS KLK3, FOLH1, ACP3 FOLH1 2/4885NAALAD2 123/4885RIMKLA 2859/4885
US-20180111895-A1 Heterodimers of Glutamic Acid DDO, GLUL, ASNS FOLH1 5/4885NAALAD2 7/4885RIMKLA 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.